Epcoritamab, a bispecific CD3xCD20 antibody, shows potential in treating refractory DLBCL-RS, offering an alternative to conventional chemotherapy with poor response rates and limited survival ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback